Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women
The purpose of this investigational study is to determine if a study medication is safe and effective in reducing the symptoms associated with endometriosis; if the study medication reduces the need for pain medication for endometriosis symptoms; and if the study medication improves a participant's ability to carry out daily activities. Qualified participants will receive no cost treatment, which may include study-related examinations, diagnostic procedures including a Pap smear, laboratory testing, and a mammogram (aged 40-45). Qualified participants will also receive study medication at no cost. As a participant, the study volunteer may also experience the satisfaction of knowing she is helping the advancement of women's health care.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
|Official Title:||A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study of the Effect of ERB-041 in the Reduction of Symptoms Associated With Endometriosis in Reproductive-Age Women|
- To assess the effects and to compare the safety profile of an investigational
- medication on the relief of endometriosis-related symptoms.
- Clinical and subject assessment of symptoms related to endometriosis and the
- use of analgesia to relieve symptoms.
|Study Start Date:||January 2005|
|Study Completion Date:||December 2006|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00110487
Show 46 Study Locations
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|